针对阿尔茨海默病的多目标治疗框架:综合性机制性审查
Ousman Bajinka1, Lamarana Jallow2, Guven Ozdemir3
1School of Medicine and Allied Health Sciences, University of The Gambia, Banjul, Gambia (the).
Neuroscience
|January 11, 2026
概括
阿尔茨海默病是一种网络障碍. 针对粉样蛋白,蛋白和其他因素的结合疗法比单独治疗阿尔茨海默病的疗法更有好处.
科学领域:
- 神经科学是一个神经科学.
- 系统生物学 系统生物学
- 老年学是指老年学的学科.
背景情况:
- 阿尔茨海默病 (AD) 是一种复杂的多因素网络疾病.
- 关键的相互作用病理包括粉样蛋白和,以及线粒体功能障碍,神经炎症,代谢问题,血管问题和突触失败.
研究的目的:
- 提供AD机制的综合性,系统级合成.
- 突出这些相互连接的途径的诊断和治疗影响.
主要方法:
- 对2010-2025年的研究进行了结构化的叙事审查.
- 搜索的数据库包括PubMed,Scopus,科学网络和Embase.
- 证据综合侧重于跨系统相互作用和翻译相关性.
主要成果:
- 汇聚的数据揭示了一个自我强化的神经退行性网络,涉及Aβ,tau,质细胞,胰岛素耐药性,线粒体功能障碍,脂质失衡和血脑屏障 (BBB) 功能障碍.
- 诊断方面的进步 (例如,血p-tau,Aβ42 / 40比率,GFAP) 允许更早的分期和个性化治疗选择.
- 与单个目标方法相比,多目标治疗策略,结合抗粉样蛋白/tau剂,质调节剂,代谢干预和生活方式计划,显示出增强的生物标志物和认知效应.
结论:
- 有效的阿尔茨海默病管理需要以系统为导向的治疗方法.
- 干预措施应根据机械主导,生物标志物阶段和协同潜力量身定制.
- 未来的研究应侧重于生物标志物引导的分层,优化治疗序列和预防的组合设计.
更多相关视频
09:47Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
Published on: December 15, 2023
1.7K
08:27Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein
Published on: July 29, 2018
12.5K
相关概念视频
Alzheimer's Disease: Treatment
801
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
801
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
